<DOC>
	<DOCNO>NCT00704366</DOCNO>
	<brief_summary>This dose escalation study assess safety tolerability AZD0530 patient advance solid malignancy .</brief_summary>
	<brief_title>AZD0530 Study 21 - Phase I Study Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Histologically cytologically confirm advanced carcinoma / solid tumour know primary site , refractory standard therapy standard therapy exist World Health Organisation ( WHO ) performance status 0 2 Life expectancy least 12 week Inadequate bone marrow reserve Inadequate liver function , renal function low hemoglobin Unresolved toxicity anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Advanced carcinoma</keyword>
</DOC>